This is a lot to process, especially at 27 — but it helps to understand what's happening and why this switch might be recommended.
Larotrectinib (Vitrakvi) is a TRK inhibitor, meaning it targets the NTRK gene fusion driving the cancer. It's been doing its job for 4.5 years, which is actually a really meaningful stretch of Show Full Answer
This is a lot to process, especially at 27 — but it helps to understand what's happening and why this switch might be recommended.
Larotrectinib (Vitrakvi) is a TRK inhibitor, meaning it targets the NTRK gene fusion driving the cancer. It's been doing its job for 4.5 years, which is actually a really meaningful stretch of stability.
However, over time, cancer cells can develop resistance to a targeted therapy — essentially finding a workaround. When that happens, doctors look for the next best option. Repotrectinib (Augtyro) is a next-generation TRK inhibitor. It's specifically designed to work even when resistance to earlier TRK inhibitors like Vitrakvi has developed. This is likely why the oncology team is recommending the switch — it targets the same NTRK fusion but is built to overcome resistance.
Key things worth discussing with the oncology team:
- Why now? Ask if recent scans or tests showed signs of progression or resistance
- What to expect from repotrectinib in terms of side effects vs. Vitrakvi
- Whether lymph node involvement changes the treatment plan beyond just switching drugs
- Clinical trials — are there any additional options worth exploring? The switch isn't a step backward — it's actually a sign that the team is staying ahead of the cancer. Repotrectinib is an approved option for exactly this kind of situation, and having a next-line targeted therapy available is genuinely good news.
As always, the oncology team is the best guide here, but going into that conversation armed with questions makes a real difference.
September 3
Join
Your Privacy Choices
